Sanofi Gains Therapeutic Cancer Vaccine TroVax In Deal With Oxford BioMedica
Announcement of the $690 million deal comes one day ahead of an advisory committee meeting for Provenge, the first therapeutic cancer vaccine to reach FDA.
Announcement of the $690 million deal comes one day ahead of an advisory committee meeting for Provenge, the first therapeutic cancer vaccine to reach FDA.